Citadel Advisors
TMDX icon

Citadel Advisors’s Transmedics TMDX Stock Holding History

Citadel Advisors’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.48M Sell
95,400
-27,400
-22% -$3.57M ﹤0.01% 3333
2025
Q4 		$14.9M Sell
122,800
-117,500
-49% -$14.7M ﹤0.01% 2709
2025
Q3 		$27M Sell
240,300
-39,800
-14% -$4.66M ﹤0.01% 1979
2025
Q2 		$37.5M Buy
280,100
+8,400
+3% +$922K 0.01% 1474
2025
Q1 		$18.3M Sell
271,700
-34,600
-11% -$2.38M ﹤0.01% 2146
2024
Q4 		$19.1M Buy
306,300
+204,600
+201% +$19M ﹤0.01% 2203
2024
Q3 		$16M Buy
101,700
+52,800
+108% +$8.14M ﹤0.01% 2306
2024
Q2 		$7.37M Sell
48,900
-11,300
-19% -$1.36M ﹤0.01% 3205
2024
Q1 		$4.45M Buy
60,200
+48,700
+423% +$4.01M ﹤0.01% 4122
2023
Q4 		$908K Sell
11,500
-9,400
-45% -$567K ﹤0.01% 6867
2023
Q3 		$1.14M Buy
20,900
+6,300
+43% +$454K ﹤0.01% 6291
2023
Q2 		$1.23M Buy
14,600
+1,500
+11% +$115K ﹤0.01% 6042
2023
Q1 		$992K Buy
13,100
+3,000
+30% +$207K ﹤0.01% 6800
2022
Q4 		$623K Sell
10,100
-10,400
-51% -$553K ﹤0.01% 7788
2022
Q3 		$856K Buy
+20,500
New +$892K ﹤0.01% 7332
2022
Q2 		– Sell
-8,600
Closed -$232K – 14106
2022
Q1 		$232K Sell
8,600
-11,000
-56% -$197K ﹤0.01% 11175
2021
Q4 		$376K Sell
19,600
-8,100
-29% -$203K ﹤0.01% 10393
2021
Q3 		$917K Sell
27,700
-9,200
-25% -$281K ﹤0.01% 8377
2021
Q2 		$1.22M Sell
36,900
-36,000
-49% -$998K ﹤0.01% 7811
2021
Q1 		$3.02M Buy
72,900
+38,800
+114% +$1.19M ﹤0.01% 5433
2020
Q4 		$679K Buy
+34,100
New +$505K ﹤0.01% 7560

Other funds holding TMDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's TMDX Position: Q1 2026 in Review

Citadel Advisors reduced its Transmedics (TMDX) stake by 57% in Q1 2026, selling an estimated $10.6M and leaving 61,601 shares worth $6.12M. The position accounts for ﹤0.01% of the portfolio, ranked #4015.

Citadel Advisors first reported a position in TMDX in Q2 2019 and has held it in 24 quarters since. The position peaked at $41M in Q1 2025. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

  • Citadel Advisors held 61,601 shares of Transmedics worth $6.12M as of Q1 2026.
  • Citadel Advisors sold 81,646 Transmedics shares in Q1 2026, an estimated $10.6M.
  • Transmedics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4015 holding.
  • Citadel Advisors first reported a position in Transmedics in Q2 2019 and has held it in 24 quarters since.
  • Citadel Advisors's Transmedics position peaked at $41M in Q1 2025.
  • 414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.